Litigation Details for VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2018)

VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2018)

Docket	3:18-cv-17246	Date Filed	2018-12-14
Court	District Court, D. New Jersey	Date Terminated	2019-04-15
Cause	35:271 Patent Infringement	Assigned To	Peter G. Sheridan
Jury Demand	None	Referred To	Lois H. Goodman
Parties	AMNEAL PHARMACEUTICALS LLC
Patents	10,105,444; 8,039,494; 8,486,978; 9,566,272; 9,662,394; 9,861,698; 9,877,955
Link to Docket	External link to docket

Details for VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-12-14				External link to document

Litigation summary and analysis for: VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2018)

Last updated: July 23, 2026

Valiant Pharmaceuticals North America LLC v. Amneal Pharmaceuticals LLC (3:18-cv-17246): Litigation Summary, Status, and Patent-Exposure Analysis

Executive summary: VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. AMNEAL PHARMACEUTICALS LLC, No. 3:18-cv-17246 is a U.S. Hatch-Waxman patent infringement suit that targets a proposed Amneal generic entry. The litigation posture is typical of Paragraph IV cases: Valeant asserts Orange Book-listed patents tied to the brand product, Amneal challenges infringement and/or validity, and the case tracks to a final adjudication and/or resolution through settlement, consent judgment, or dismissal. No reliable docket disposition or claim-by-claim ruling content is available in the provided record, so a complete, accurate event-by-event litigation summary and merits analysis cannot be produced without introducing unverified facts.

What happened in Valeant v. Amneal, 3:18-cv-17246? (case chronology and core issues)

Featured snippet answer: The action is filed in federal court as a patent infringement case arising from FDA generic approval-related activities, with the brand asserting listed patents and the generic contesting infringement and/or validity under Hatch-Waxman.

What court and procedural posture does this case reflect?

• Case number: 3:18-cv-17246
• Caption: VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. AMNEAL PHARMACEUTICALS LLC
• Nature: Hatch-Waxman-type patent infringement litigation tied to an ANDA AND an Orange Book patent list (Paragraph IV framework is the standard mechanism for these filings).

How do these cases typically frame the issues?

• Valeant’s claims: infringement of one or more Orange Book-listed patents covering the reference listed drug (RLD), often including one or more of:
  • composition or formulation claims,
  • method-of-use claims,
  • process/manufacturing claims.
• Amneal’s defenses:
  • non-infringement (no corresponding limitation in the proposed generic),
  • invalidity (anticipated by prior art, obviousness, indefiniteness/enablement, lack of written description, or improper claim scope),
  • statutory non-infringement carveouts and/or claim construction narrowing.

Which patents are at issue in Valeant v. Amneal (3:18-cv-17246)?

Featured snippet answer: This depends on the specific Orange Book listing(s) and the asserted patent list in Valeant’s infringement complaint. Without the asserted patent numbers or the docket’s complaint exhibit content, a precise patent-by-patent identification cannot be stated accurately.

How to map Hatch-Waxman litigation to the asserted patent basket

In Paragraph IV cases, the asserted estate generally includes:

• drug substance/composition patents (active ingredient or salt form, polymorphs, stabilizers),
• formulation patents (excipients, release profile, particle-size ranges),
• method-of-use patents (dose, indication, patient population),
• combination patents (if the RLD is combination therapy),
• manufacturing/process patents (granulation, milling, coating, sterilization parameters).

Common claim types and litigation impact

• Composition/formulation claims: usually drive claim construction and infringement mapping of generic formulation specs.
• Method-of-use claims: usually pivot on label-based infringement and FDA labeling carveouts.
• Process claims: often litigated with proposed manufacturing steps and expert characterization.

What is the case status for 3:18-cv-17246 (dismissal, settlement, or judgment)?

Featured snippet answer: A complete and accurate status statement (e.g., motion outcomes, consent judgment, settlement date, or final court disposition) cannot be produced from the provided information.

What statuses matter for exclusivity and generic launch risk

For downstream licensing, investment, and generic-entry planning, the high-signal docket milestones are:

• Pleadings stage: complaint and answer, patent list amendments if any.
• Claim construction: Markman order affecting infringement viability.
• Summary judgment: validity/infringement rulings that narrow trial issues.
• Trial verdict: ultimate merits outcomes.
• Final judgment or consent decree: often triggers appeal clocks.
• Settlement/covenant not to sue: changes launch timing and design-around strategy.

How strong is Valeant’s patent position in this litigation?

Featured snippet answer: Patent strength cannot be evaluated without the asserted patent claims, their expiration status, the court’s claim construction, and any validity rulings.

What decides “strength” in a Hatch-Waxman patent infringement case

• Claim construction outcomes: narrower interpretations can kill infringement.
• Validity posture: prior art strength, enablement, written description, and obviousness evidence.
• Terminal disclaimer or prosecution history: can limit claim scope.
• Claim overlap with known generic formulations: affects infringement likelihood.

What “strength” typically looks like in these litigations

Courts commonly determine:

• whether the proposed generic’s product characteristics read on each claim limitation,
• whether challenged claims are anticipated or obvious,
• whether the patent is enforceable against the accused product.

Did Amneal file a Paragraph IV ANDA challenge tied to this lawsuit?

Featured snippet answer: The lawsuit is consistent with Paragraph IV frameworks, but the specific ANDA number, filing date, and whether the litigation was triggered by a Paragraph IV notice cannot be confirmed from the provided record.

Why ANDA identification matters

• ANDA identification ties to:
  • the exact proposed formulation,
  • the FDA approval pathway,
  • the likely label and strength(s) at issue,
  • the launch eligibility date if patents are invalidated or not infringed.

What generic entry risks exist for Amneal after Valeant v. Amneal, 3:18-cv-17246?

Featured snippet answer: Launch timing and entry risk depend on:

• whether the case results in a stay/lifting of injunction,
• whether any patents are held not infringed or invalid,
• settlement terms (design-around, delayed entry, royalties, or specific launch dates).

How courts and settlements typically translate into market timing

Hatch-Waxman litigations feed into launch risk through:

• injunction terms (rare postures in settled cases but possible),
• early entry agreements or delayed launch calendars,
• design-around requirements (formulation, dosing, process changes).

How do settlement agreements (if any) affect Valeant vs. Amneal’s market timelines?

Featured snippet answer: Settlement effects cannot be stated without the settlement date and the terms (trigger conditions, covenants, product design constraints, and payment structure).

Key settlement clauses that drive compliance

In practice, the terms that materially affect future freedom-to-operate include:

• permitted strengths, dosage forms, and NDCs,
• labeling positions and carveouts,
• confidentiality and FDA communication limits,
• manufacturing restrictions and testing protocols,
• royalty or milestone triggers tied to launch.

What does FDA Orange Book status imply for exclusivity in this case?

Featured snippet answer: Orange Book status determines the patent list expiration and exclusivity windows, but the specific RLD and listed patents are not provided.

Why Orange Book data is central

• If the asserted patents expire or are invalidated, the generic entry risk typically drops sharply.
• If method-of-use patents or unexpired formulation patents remain, entry may still be blocked or require labeling carveouts.

Which company competitors are likely affected by the outcome?

Featured snippet answer: Any competitor marketing competing generics of the same RLD (or filing the same ANDA family) is potentially affected, but the specific product and patent claims determine the competitive set.

How to infer the competitor set in Hatch-Waxman disputes

The competitor universe typically includes:

• other Paragraph IV filers on the same RLD,
• companies with approved ANDAs or pending amendments,
• authorized generics if they track the same entry path.

Key takeaway timeline framework for 3:18-cv-17246 (patent and launch planning)

Featured snippet answer: Build a project timeline around (i) patent expiration, (ii) any injunction/consent order dates, (iii) settlement-driven launch authorization, and (iv) FDA approval timing.

High-signal dates to extract from the docket

• Complaint filing date: 2018 (based on case number year)
• Answer and counterclaims dates
• Claim construction schedule and Markman order date
• Summary judgment/trial events (if any)
• Final judgment date or dismissal/consent date
• Any appeal and stay dispositions

Note: A specific date-by-date timeline cannot be populated from the provided record.

Key Takeaways

• Case identification: VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. AMNEAL PHARMACEUTICALS LLC, 3:18-cv-17246 is a Hatch-Waxman-style patent dispute.
• Deciding details missing: asserted patent numbers, claim construction outcomes, and final disposition are not included in the provided information.
• Actionability depends on docket exports: a defensible patent-expiration and generic-launch risk analysis requires the complaint’s asserted patent list and the docket’s resolution details.

FAQs

1. What patents are typically asserted by Valeant in its Hatch-Waxman suits against generics?
2. How do claim construction orders usually change outcomes in ANDA Paragraph IV infringement cases?
3. What docket events most reliably predict generic launch timing after a Valeant v. Amneal action?
4. When do settlements in Hatch-Waxman cases allow “design-around” and partial entry?
5. How should method-of-use patents influence FDA label carveout strategies for an accused generic?

References (APA)

1. Valeant Pharmaceuticals North America LLC v. Amneal Pharmaceuticals LLC, 3:18-cv-17246. U.S. District Court docket.